# Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT02530502** · PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 4 (actual)

## Conditions studied

- Adult Glioblastoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02530502
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-30
- **Primary completion:** 2016-05-10
- **Final completion:** 2020-02-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The protocol was amendment to be stopped after phase I (phase 2 removed from protocol)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02530502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02530502, "Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02530502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*